NEW YORK, Aug. 31, 2023 /PRNewswire/ — The bioprocess validation market is set to grow by USD 280.93 million from 2022 to 2027. However, the growth momentum will progress at a CAGR of 11.39% during the forecast period, according to Technavio. The bioprocess validation market is fragmented, and the vendors are seeking strong partnerships with automotive, industrial, and commercial companies to compete in the market. Agilent Technologies Inc., Asahi Kasei Corp., Avantor Inc., Bangalore Biotech Labs Pvt. Ltd., Charles River Laboratories International Inc., Corning Inc., Danaher Corp., Eurofins Scientific SE, GEA Group AG, Hangzhou Cobetter Filtration Equipment Co. Ltd., Laboratory Corp. of America Holdings, Lonza Group Ltd., Meissner Filtration Products Inc., Merck KGaA, Porvair Plc, ProPharma Group Holdings LLC, Sartorius AG, SGS SA, Thermo Fisher Scientific Inc., and W. L. Gore and Associates Inc. are some of the major market participants -. To know about the company offerings – Request a sample report

Bioprocess Validation Market 2023-2027: Drivers & Challenges

The increasing demand for biopharmaceuticals drives the market growth. The demand for biopharmaceuticals in the healthcare sector is increasing, and to ensure consistency, the production of high-quality products that deliver efficacy and patient safety can be achieved by validation. For instance, the bioproduction of monoclonal antibodies is one of the major examples where validation of a biological process has a significant impact. Additionally, a well-designed biological process validation plan is the most important factor in ensuring that the final product meets the required standards and regulatory specifications. Hence, such factors are expected to drive market growth during the forecast period.

High costs associated with bioprocess validation challenge market growth. The three main categories for costs associated with biological process validation are equipment, personnel, and time. For instance, specialized equipment, such as bioreactors, chromatographic systems, and mass spectrometers, among others are required to validate a biological process. Such devices can be expensive or affordable to purchase, maintain, and calibrate. Hence, the high cost of bioprocess validation is expected to restrict market growth during the forecast period.

To learn more about the global trends impacting the future of market research, download a PDF sample

Bioprocess Validation Market 2023-2027: Segment Analysis

• End-user 
• Pharmaceutical Companies
• Contract Development And Manufacturing Organizations
• Others
• Type 
• In-house
• Outsourced
• Geography 
• North America
• Europe
• Asia
• Rest Of World (ROW)

Bioprocess Validation Market 2023-2027: Segmentation Highlights

The pharmaceutical companies segment will be significant during the forecast period. Pfizer, Johnson, Johnson (J&J), and Novartis AG (Novartis) are some of the major pharmaceutical companies having a significant impact on the bioprocess validation market. This impact is attributed to their vast resources, expertise, and experience in this field. Furthermore, factors like the development of complex and innovative biological products is one of the key contributions of major pharmaceutical companies to the bioprocess validation market. Hence, such factors drive the growth of this segment in the market during the forecast period.

 Buy the Report

Bioprocess Validation Market 2023-2027: Key Highlights

• CAGR of the market during the forecast period 2023-2027
• Detailed information on factors that will assist bioprocess validation market growth during the next five years
• Estimation of the bioprocess validation market size and its contribution to the parent market
• Predictions on upcoming trends and changes in consumer behavior
• The growth of the bioprocess validation market across North America, Europe, Asia, and Rest of World (ROW)
• Analysis of the market’s competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of bioprocess validation market vendors

Get Instant access to 17000+ market research report

 Technavio’s Subscription Platform

Related Reports:

The recombinant proteins market is estimated to grow at a CAGR of 9.46% between 2022 and 2027. The market size is forecast to increase by USD 650.96 million. Furthermore, this report extensively covers market segmentation by application (biotechnology research, drug discovery and development, biopharmaceutical production, and others), end-user (pharma and biotechnology companies, academic and research institutes, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)). Growing opportunities from emerging economies is a key trend influencing the recombinant proteins market growth.

The biochips market is estimated to grow by USD 43,273.01 million between 2022 and 2027 accelerating at a CAGR of 25.15% during the forecast period. Furthermore, this report extensively covers market segmentation by end-user (biotechnology and pharmaceutical companies, hospitals and diagnostics centers, and academic and research institutes), technology (microarrays and microfluidics), and geography (North America, Europe, APAC, Middle East and Africa, and South America). The growing applications of microarray biochips in drug discovery is a key factor driving market growth during the forecast period.

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by End-user

7 Market Segmentation by Type

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Trends

11 Vendor Landscape

12 Vendor Analysis

13 Appendix

About US

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]

Website: www.technavio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/bioprocess-validation-market-to-grow-by-usd-280-93-million-from-2022-to-2027–agilent-technnologies-inc-avantor-inc-and-corning-inc-are-some-of-the-market-key-players—technavio-301913937.html

SOURCE Technavio

Featured image: Megapixl © Lucadp

Disclaimer